Literature DB >> 21610564

Functional and morphologic benefits in early detection of neovascular age-related macular degeneration using the preferential hyperacuity perimeter.

Yuhua Lai1, Joanne Grattan, Yanyun Shi, Graham Young, Alyson Muldrew, Usha Chakravarthy.   

Abstract

PURPOSE: To estimate the usefulness of preferential hyperacuity perimetry (PHP) in detecting conversion of early to late age-related macular degeneration in the Carotenoids and co-antioxidants in patients with Age-Related Maculopathy, a multicenter randomized controlled clinical trial.
METHODS: This was a nested case control study within the Carotenoids and co-antioxidants in patients with Age-Related Maculopathy (CARMA) clinical trial and included all participants enrolled in a single center (n = 200). Data are from participants who progressed to neovascular age-related macular degeneration (nvAMD) during time on study, Group 1 (n = 10) before the use of PHP and Group 2 (n = 10) during use of PHP. We also randomly selected 21 other participants (Group 3) who did not progress to nvAMD during time on study as a control group. Change in best-corrected visual acuity and contrast sensitivity and size of neovascular lesion at detection of conversion to nvAMD in Groups 1 and 2.
RESULTS: At detection of nvAMD, mean best-corrected visual acuity in Group 1 was 57.5 letters versus 67.4 in Group 2. In Group 1, the change in best-corrected visual acuity from baseline to detection of nvAMD was twice that of Group 2 (21.6 ± 9.0 versus 11.9 ± 10.7) with a mean difference of 9.7 letters (95% confidence interval, 0.41 to 19.0, P = 0.04, independent-samples t-test). The size of the neovascular lesion at detection was 3.06 mm in Group 1 versus 0.89 mm in Group 2 (P = 0.02). Two thirds of the participants in Group 2 were asymptomatic at detection of nvAMD compared with one fifth in Group 1. Preferential hyperacuity perimetry distortion maps were abnormal in 9 of 10 eyes in Group 2, which were confirmed by optical coherence tomography. Of the 21 eyes in Group 3, PHP maps were normal in 18 and abnormal in 3.
CONCLUSION: Preferential hyperacuity perimetry detected abnormalities in central visual function with high reliability. Eyes with nvAMD lesions detected by PHP had smaller lesions and better function when compared with the group before the introduction of PHP. The false-negative rate was <10% on PHP. The PHP distortion map was helpful in alerting clinicians to the presence of subclinical nvAMD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21610564     DOI: 10.1097/IAE.0b013e31820d3ed1

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  5 in total

Review 1.  Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis.

Authors:  L Faes; N S Bodmer; L M Bachmann; M A Thiel; M K Schmid
Journal:  Eye (Lond)       Date:  2014-05-02       Impact factor: 3.775

Review 2.  Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.

Authors:  Jennifer R Evans; John G Lawrenson
Journal:  Cochrane Database Syst Rev       Date:  2017-07-31

3.  Assessment of visual distortions in age-related macular degeneration: emergence of new approaches.

Authors:  Noelia Pitrelli Vazquez; Paul C Knox
Journal:  Br Ir Orthopt J       Date:  2015

4.  Improved Adherence to Vision Self-monitoring with the Vision and Memory Stimulating (VMS) Journal for Non-neovascular Age-related Macular Degeneration during a Randomized Controlled Trial.

Authors:  Ava K Bittner; Sheryl Torr-Brown; Ellen Arnold; Antonia Nwankwo; Patricia Beaton; Radhika Rampat; Gislin Dagnelie; Mark Roser
Journal:  J Clin Exp Ophthalmol       Date:  2014-01-22

Review 5.  Recent Advances of Computerized Graphical Methods for the Detection and Progress Assessment of Visual Distortion Caused by Macular Disorders.

Authors:  Navid Mohaghegh; Ebrahim Ghafar-Zadeh; Sebastian Magierowski
Journal:  Vision (Basel)       Date:  2019-06-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.